SymbolOBIO
NameORCHESTRA BIOMED HOLDINGS, INC.
SectorHEALTH CARE
RegionNorth America
Industry Medicinal Chemicals and Botanical Products
Address150 UNION SQUARE DRIVE, NEW HOPE, Pennsylvania, 18938, United States
Telephone+1 215 - 862-5797
Fax
Email
Websitehttps://www.orchestrabiomed.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001814114
Description

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Additional info from NASDAQ:
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

2026-06-12 20:16

Taylor Andrew Lawrence 🔴 sold 36.4K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.02 Transaction Date: Jun 10, 2026 | Filing ID: 073476

Read more
2026-06-12 20:15

Director Hochman David P 🔴 sold 6.6K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.02 Transaction Date: Jun 10, 2026 | Filing ID: 073468

Read more
2026-06-02 20:28

Director Hochman David P 🟢 acquired 5.0K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.83 Transaction Date: Jun 01, 2026 | Filing ID: 069510

Read more
2026-06-02 20:27

Director Sherman Darren 🔴 sold 15.0K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.87 Transaction Date: Jun 01, 2026 | Filing ID: 069503

Read more
2026-06-02 20:05

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-01 20:16

📋 Sherman Darren (Officer) plans to sell 15K shares of Orchestra BioMed Holdings, Inc. (at $3.87 each, total $58K) Filed: Jun 01, 2026 | ID: 004222

Read more
2026-05-29 20:15

Taylor Andrew Lawrence 🔴 sold 3.1K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.98 Transaction Date: May 28, 2026 | Filing ID: 068278

Read more
2026-05-20 12:00

Director Aryeh Jason 🟢 acquired 665 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.75 Transaction Date: May 18, 2026 | Filing ID: 064136

Read more
2026-05-19 12:30

Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference

Read more
2026-05-19 12:00

Director Aryeh Jason 🟢 acquired 9.0K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.90 Transaction Date: May 15, 2026 | Filing ID: 063511

Read more